OncoImmunology · 2016 · 38 citations · 25 references
PharmacyImmunologyOncologyImmunotherapyMonoclonal AntibodiesProtein EngineeringAntibody Fragment EngineeringAntibody StructureAntibody-antigen RecognitionCancer ImmunotherapyTherapeutic Antibody DevelopmentTherapeutic Monoclonal AntibodiesAntitumor Immune ActivationFusion Protein DesignReceptor-fusion Protein DesignRecombinant Fusion ProteinsSingle-chain Variable FragmentsTherapeutic Targeting Of Fusion ProteinsTumor Necrosis Factor SuperfamilyTumor-targeted Ligands
Co-stimulation via receptors of the tumor necrosis factor superfamily (TNFSF) emerges as promising strategy to support antitumor immune responses. Targeted strategies with antibody-fusion proteins composed of a tumor-directed antibody part and the extracellular domain of a co-stimulatory ligand of the TNFSF constitute an attractive option to focus the co-stimulatory activity to the tumor site. Since TNFSF members intrinsically form functional units of non-covalently linked homotrimers, the protein engineering of suitable antibody-fusion proteins is challenging. Aiming for molecules of simple and stable configuration, we used TNFSF ligands in a single-chain format (scTNFSF), i.e., three units of the ectodomain connected by polypeptide linkers, folding into an intramolecular trimer. By fusing tumor-directed scFv antibody fragments directed against EpCAM or FAP to co-stimulatory scTNFSF molecules (sc4-1BBL, scOX40L, scGITRL or scLIGHT), a set of monomeric scFv-scTNFSF fusion proteins was generated. In comparison to the scFv-TNFSF format, defined by intermolecular homotrimerization via the TNFSF part, scFv-scTNFSF showed equal or enhanced co-stimulatory activity despite reduced avidity in antibody binding. In addition, enhanced serum stability and improved bioavailability in mice were observed. We show that the scFv-scTNFSF format can be applied to various members of the TNFSF, presenting targeting-dependent co-stimulatory activity. Hence, this format exhibits favorable properties that make it a promising choice for further therapeutic fusion protein development.
25
Claudia Bluemel, Susanne Hausmann, Petra Fluhr et al. · Cancer Immunology Immunotherapy · 2010 · 206 citations · Full text
Life Sciences, Immunology, Oncology +17
The Crystal Structure of the Costimulatory OX40-OX40L Complex
Deanne M. Compaan, S.G. Hymowitz · Structure · 2006 · 144 citations · Full text
Agnes Wyzgol, Nicole Müller, Andrea Fick et al. · The Journal of Immunology · 2009 · 144 citations · Full text
Juan Dubrot, Francisca Milheiro, Carlos Alfaro et al. · Cancer Immunology Immunotherapy · 2010 · 113 citations · Full text
Life Sciences, Immunology, Oncology +17